Association of Life's Essential 8 with metabolic dysfunction-associated steatotic liver disease (MASLD), a cross-sectional study from the NHANES 2003-2018

被引:2
|
作者
Liu, Xiangliang [1 ]
Chang, Yu [1 ]
Jia, Feng [1 ]
Li, Yuguang [1 ]
Wang, Yao [1 ]
Cui, Jiuwei [1 ]
机构
[1] First Hosp Jilin Univ, 1 Xinmin St, Changchun, Peoples R China
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
Life's Essential 8 (LE8); Metabolic dysfunction-associated steatotic liver disease (MASLD); Cardiovascular Health (CVH); Weighted quantile sum regression (WQS) model; Restrictive cubic spline (RCS); NHANES; AMERICAN HEART ASSOCIATIONS; CARDIOVASCULAR-DISEASE; MEDITERRANEAN DIET; HEALTH; PREVALENCE; INDEX; COST; RISK;
D O I
10.1038/s41598-024-67728-w
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
There is limited research on the relationship between Life's Essential 8 (LE8) score and metabolic dysfunction-associated steatotic liver disease (MASLD). Our aim is to investigate the relationship between overall lifestyle assessed by LE-8 score and MASLD in a nationally representative sample. We employed the LE8 score to comprehensively evaluate cardiovascular health, the assessment of MASLD primarily utilized the Fatty Liver Index. The weighted logistic regression models, restrictive cubic splines (RCS), subgroup analyses and the weighted quantile sum (WQS) regression were used to evaluate the relationship between the cardiovascular health and MASLD. Logistic regression models revealed that higher LE8 scores were associated with lower odds of having MASLD. The RCS revealed a significant nonlinear dose-response relationship between LE8 scores and MASLD. The WQS regression model indicated that blood glucose contributed the most to the risk of MASLD. The subgroup analysis indicates that there are significant differences in this association across age, educational level, and poverty income ratio. Our study suggests that an inverse correlation between LE8 and the risk of MASLD. Our findings underscore the utility of the LE8 algorithm in MASLD risk assessment and provide support for MASLD prevention through the promotion of healthy lifestyles.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Assessment of skeletal muscle alterations and circulating myokines in metabolic dysfunction-associated steatotic liver disease: A cross-sectional study
    Martinez, Yolanda Real
    Fernandez-Garcia, Carlos Ernesto
    Fuertes-Yebra, Esther
    Calvo Soto, Mario
    Berlana, Angela
    Barrios, Vicente
    Caldas, Maria
    Gonzalez Moreno, Leticia
    Garcia-Buey, Luisa
    Molina Baena, Begona
    Sampedro-Nunez, Miguel
    Beceiro, Maria J.
    Garcia-Monzon, C.
    Gonzalez-Rodriguez, Agueda
    WORLD JOURNAL OF GASTROENTEROLOGY, 2025, 31 (07)
  • [22] Association between periodontitis and mortality in participants with metabolic dysfunction-associated steatotic liver disease: results from NHANES
    Zhaofu Zhang
    Qiuyun Zheng
    Yiheng Liu
    Guanhui Chen
    Yiming Li
    BMC Oral Health, 25 (1)
  • [23] INSULIN RESISTANCE IS A PREDICTOR OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND MASLD-ASSOCIATED FIBROSIS
    Kim, David S.
    Ismail, Mohamed
    Abboud, Yazan
    Khan, Wajiha
    Le, Alexander
    Pyrsopoulos, Nikolaos T.
    Kim, Hyunseok
    Hajifathalian, Kaveh
    GASTROENTEROLOGY, 2024, 166 (05) : S1657 - S1657
  • [24] The rise of metabolic dysfunction-associated steatotic liver disease (MASLD) among adults in Canada between 2012 and 2018
    Burnside, Jessica
    Cinque, Felice
    Sebastiani, Giada
    Saeed, Sahar
    JOURNAL OF HEPATOLOGY, 2024, 80 : S650 - S651
  • [25] Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Markowska, Julia
    Kasprzak-Drozd, Kamila
    Nizinski, Przemyslaw
    Dragan, Magdalena
    Kondracka, Adrianna
    Gondek, Ewa
    Oniszczuk, Tomasz
    Oniszczuk, Anna
    MOLECULES, 2024, 29 (22):
  • [26] Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Elshaer, Amani
    Chascsa, David M. H.
    Lizaola-Mayo, Blanca C.
    LIFE-BASEL, 2024, 14 (07):
  • [27] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Chan, Wah-Kheong
    Chuah, Kee-Huat
    Rajaram, Ruveena Bhavani
    Lim, Lee-Ling
    Ratnasingam, Jeyakantha
    Vethakkan, Shireene Ratna
    JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (03) : 197 - 213
  • [28] EATING DISORDERS IN MEXICAN POPULATION WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Contreras, Ana D. Cano
    Alvarez, Hector Ricardo Ordaz
    Priego-Parra, Bryan Adrian
    Martinez-Perez, Genesis Patricia
    Reyes-Diaz, Sara A.
    Azamar, Pamela Duran
    Garcia-Carvajal, Mario J.
    Diaz-Crespo, Angel H.
    Vazquez-Cruz, Anette P.
    Hernandez, Tonatiu Castellanos
    Basurto, Jose Luis Vargas
    Dietlen, Federico B. Roesch
    Francisco, Maria D.
    Amieva-Balmori, Mercedes
    Remes-Troche, Jose Maria
    GASTROENTEROLOGY, 2024, 166 (05) : S1649 - S1650
  • [29] ALTERED GUT VIRAL ECOLOGY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Nzabarushimana, Etienne
    Kim, Hanseul
    Jensen, Jordan
    Shen, Jiaxian
    Nelson, Paul
    Thompson, Kelsey N.
    Chan, Andrew T.
    Hayete, Boris
    Huttenhower, Curtis
    Nguyen, Long H.
    GASTROENTEROLOGY, 2024, 166 (05) : S1539 - S1540
  • [30] Evaluation of a Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Clinical Pharmacy Service
    Sallam, Sandy
    Ahmed, Aijaz
    Gu, Xin
    DIABETES, 2024, 73